Changes in serum lipoproteins were studied in 14 noninsulin dependent diabetics on long-term metformin therapy, after 6 weeks' placebo, and again 6 weeks after restarting active drug therapy. Withdrawal of metformin resulted in a rise of fasting blood glucose, HbA1, serum total and low density lipoprotein (LDL) cholesterol. Restarting the drug reversed these changes. Multivariate analysis showed that serum total and LDL cholesterol varied with treatment but not with glycaemic control Metformin can lower serum total and LDL cholesterol in non-insulin dependent diabetics and this effect is maintained long term.
Introduction
Non-insulin dependent diabetes is associated with an increased incidence of coronary heart disease'. Concentrations of total serum and low density lipoprotein (LDL) cholesterol are directly related to the incidence of coronary heart disease in the general population2, and are associated with macrovascular disase (coronary heart disease and peripheral vasular disease) in non-insulin dependent diabetics3. We have previously reported a reduction in LDL cholesterol by metformin after 3 months' therapy'. To ascertain whether this reduction in LDL cholesterol is maintained with long-term therapy, we have examined the effect of metformin withdrawal and subsequent reintroduction on serum lipoproteins in a group of non-insulin dependent diabetics on established therapy.
Patients and methods Fourteen subjects (9 males, 5 females) were recruited from the diabetic clinic. All were non-insulin dependent diabetics on established oral hypoglycaemic therapy, 9 were taking metformin alone and 5 were taking a combination of metformin and a sulphonylurea. The median duration ofmetformin therapy was 5 years with a range of 1-7 years.
Baseline samples were taken from patients on existing therapy. Then in a single blind study, patients received consecutively 6 weeks of active metformin, 6 weeks of placebo and a further 6 weeks of active drug. Prior to the study and after each drug period, fasting blood samples were taken for fasting plasma glucose, HbA1, and serum lipids and lipoproteins. Sulphonylurea dosage in those patients on combined therapy remained constant throughout the study.
Serum cholesterol and triglyceride were measured enzymatically. High density lipoprotein (BDL) cholesterol was measured in the supernate following precipitation of other lipoproteins with dextran sulphate (50 000) and magnesium5. LDL cholesterol was derived by the Friedewald equation6. Changes with therapy were analysed by Student's paired t test. The relative influences of drug and glycaemic control onwserum lipoproteins were studied by analysis of covariance.
Results
There were no significant changes in weight, blood glucose control, or lipid concentrations between baseline (existing therapy) and initial study period on metformin (Table 1 and Figure 1 ). Withdrawal of metformin resulted in an increase in fasting plasma glucose, HbA1, total cholesterol and LDL cholesterol (mean increase in LDL cholesterol; +b.58 mmol/l: 95% CI +0.19 to +0.98 mmol/l: P<0.01). There were no changes intriglyceride or HDL cholesterol. Reintroduction of metformin reversed these changes (mean fall in LDL cholesterol; -0.51 mmol/l: 95% CI -0.02 to -1.00 mmol/l: P<O.0O).
Similar changes were seen both in the patients on metfermin alone and in those on a combination of sulphonylurea and metformin.
When-the relative inifluences of drug or placebo and glycaemic control were ass-esed, total cholesterol and LDL 'cholesterol varied with treatment (F=6.86, P=0.013) but not with glycaemic control (F=0.01, P=0.921).
Discussion
In a short-term study of the effect of oral hypoglycaemic drugs on lipoproteins4, we observed a 10% fall in LDL cholesterol after 3 months' therapy with metformin. The 16% increase in LDL cholesterol on cessation of metformin seen in this study suggests mmd/l that its reduction by metformin is maintained with long-term therapy.
No alternative hypoglycaemic therapy was substituted for metformin. The lack of relationship between changes in glycaemic control and changes in LDL cholesterol, suggests that the rise in LDL cholesterol was not simply a result of a deterioration of diabetic control. In addition, a reduction of LDL cholesterol with metformin has also been reported in non-diabetics7. It, therefore, seems likely that metformin has an LDL cholesterol lowering effect, which is separate from its effect on blood glucose.
In contrast to the microvascular complications, the macrovascular complications ofnon-insulin dependent diabetes have not been shown to be retarded by good diabetic control8. It would, therefore, seem sensible that the management of non-insulin dependent diabetes should include the improvement of all cardiovascular risk factors which are amenable to treatment. LDL cholesterol is an important risk factor for coronary heart disease, and its reduction by metformin suggests a possible role for this drug in the long-term prevention ofcoronary heart disease in noninsulin dependent diabetes.
